COMPARING OF FAECAL CALPROTECTIN LEVELS IN PATIENTS WITH OSTEOARTHRITIS TAKING NSAID TREATMENT AND PATIENTS WITHOUT NSAIDS THERAPY
Faecal calprotectin (FC) level can be increased in several conditions, which are characterised by neutrophilic inflammation. Some medications, particularly NSAIDs, can elevate its level as well. NSAIDs are taken by patients in many chronic conditions, including osteoarthritis (OA).
On the other hand, there is growing evidence that osteoarthritis is not only a degenerative disease, but it has a significant inflammatory component. The role of systemic inflammation is well-known in inflammatory joint diseases, but there is some evidence that it can play an essential role in the OA as well. It can suggest that in the OA, the inflammatory changes could be found in the different organs and systems.
The aim of this study was to investigate the FC level in patients with osteoarthritis depending on the NSAIDs intake and to compare it to the FC levels in healthy adults.
Materials and methods. In this small observational study, we evaluated the FC levels in patients suffering from OA (36 persons), divided them into two groups depending on their NSAIDs intake, and compared it to FC levels in healthy participants (12 persons). We compared the FC levels depending on the selectivity of the NSAIDs taken by our participants, as well.
Results. The median calprotectin level in our patients was 72.57 (IQR 20.55-221.57) mg/kg, 95 %CI 26,18-109.01. OA patients had higher levels than the healthy group (p<0.001). OA patients who took NSAIDs had the highest FC levels – 221.57 (IQR 91.56-448.61) – higher, than those who did not take it – 72.57 (IQR 35.26-164.79) (p=0.03) and than healthy participants, who has normal FC levels (p<0.001); the FC levels of patients who did not take NSAIDs also exceeds healthy subject’s levels (p<0.001). The FC levels in the collective group have a sufficient positive correlation with the duration of NSAIDs intake, VAS score and strong correlation with Lequesne index values. We found that both NSAIDs groups have a significantly greater prevalence of elevated or high FC levels than the control group (p<0.001) and that NSAIDs patients significantly more often have high FC levels than those who do not take NSAIDs (p=0.035). When comparing FC levels in patients depending on the type of NSAIDs they take, we found that those who take non-selective NSAIDs has significantly higher FC levels than those who do not take NSAIDs – 264.1 (IQR 89.72-464.67) to 25.65 (IQR 19.5-75.33) (p=0.0003). The FC levels of who take selective NSAIDs – 98.53 (91.56-105.5) – did not differ significantly to non-selective NSAIDs taker’s group values and non-selective NSAIDs taker’s values (p>0.05).
Conclusions. Patients who suffer from OA have higher FC levels than healthy individuals, and patients with OA who take NSAIDs regularly have higher FC levels than those who do not. The intake of non-selective NSAIDs is associated with higher FC levels, than the intake of high-selective NSAIDs. FC levels of those who take high-selective NSAIDs do not differ statistically from those who do not intake NSAIDs. Further research is needed in this area.
Wallace, J. L. (2013). Polypharmacy of Osteoarthritis: The Perfect Intestinal Storm. Digestive Diseases and Sciences, 58 (11), 3088–3093. doi: http://doi.org/10.1007/s10620-013-2777-8
Blackler, R. W., Gemici, B., Manko, A., Wallace, J. L. (2014). NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Current Opinion in Pharmacology, 19, 11–16. doi: http://doi.org/10.1016/j.coph.2014.05.008
Balabanceva, A., Klyaritskaya, I., Tkach, S., Kuzenko, Y. (2014). SAT0117 Reduction of Nsaid-Induced Small Intestinal Damage in Rheumatoid Arthritis Patients Receiving Sulfasalazine. Annals of the Rheumatic Diseases, 73 (2), 633. doi: http://doi.org/10.1136/annrheumdis-2014-eular.1671
Gubska, O. J., Kuzminets, A. A. (2018). NSAID-enterotoxicity: focus on the problem. Modern Gastroenterology, 5, 50–59. doi: http://doi.org/10.30978/mg-2018-5-50
Lim, Y. J., Yang, C.-H. (2012). Non-Steroidal Anti-Inflammatory Drug-Induced Enteropathy. Clinical Endoscopy, 45 (2), 138–144. doi: http://doi.org/10.5946/ce.2012.45.2.138
Sostres, C., Gargallo, C. J., Lanas, A. (2013). Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Research & Therapy, 15 (3), 3. doi: http://doi.org/10.1186/ar4175
Costa, F., Mumolo, M. G., Bellini, M., Romano, M. R., Ceccarelli, L., Arpe, P. et. al. (2003). Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Digestive and Liver Disease, 35 (9), 642–647. doi: http://doi.org/10.1016/s1590-8658(03)00381-5
Maiden, L., Thjodleifsson, B., Theodors, A., Gonzalez, J., Bjarnason, I. (2005). A Quantitative Analysis of NSAID-Induced Small Bowel Pathology by Capsule Enteroscopy. Gastroenterology, 128 (5), 1172–1178. doi: http://doi.org/10.1053/j.gastro.2005.03.020
Thornjóðleifsson, B., Theodórs, A., Bjarnason, I. (2004). The effect of diclofenac on the small intestine studied by wireless endoscopy. Laeknabladid, 90 (10), 689–693. Available at: http://europepmc.org/abstract/MED/16819054
Tibble, J. A., Sigthorsson, G., Foster, R., Scott, D., Fagerhol, M. K., Roseth, A., Bjarnason, I. (1999). High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut, 45 (3), 362–366. doi: http://doi.org/10.1136/gut.45.3.362
Meling, T. R., Aabakken, L., Røseth, A., Osnes, M. (1996). Faecal Calprotectin Shedding after Short-Term Treatment with Non-Steroidal Anti-Inflammatory Drugs. Scandinavian Journal of Gastroenterology, 31 (4), 339–344. doi: http://doi.org/10.3109/00365529609006407
Takeuchi, K., Smale, S., Premchand, P., Maiden, L., Sherwood, R., Thjodleifsson, B. et. al. (2006). Prevalence and Mechanism of Nonsteroidal Anti-Inflammatory Drug–Induced Clinical Relapse in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 4 (2), 196–202. doi: http://doi.org/10.1016/s1542-3565(05)00980-8
Lee, I. S., Cho, Y. K. (2015). Initial Steps to Prevent Nonsteroidal Anti-Inflammatory Drug- or Aspirin-Induced Enteropathy: Long-Term Outcome Data. Gut and Liver, 9 (6), 697. doi: http://doi.org/10.5009/gnl15287
Carroccio, A., Iacono, G., Cottone, M., Di Prima, L., Cartabellotta, F., Cavataio, F. et. al. (2003). Diagnostic Accuracy of Fecal Calprotectin Assay in Distinguishing Organic Causes of Chronic Diarrhea from Irritable Bowel Syndrome: A Prospective Study in Adults and Children. Clinical Chemistry, 49 (6), 861–867. doi: http://doi.org/10.1373/49.6.861
D’Angelo, F., Felley, C., Frossard, J. L. (2017). Calprotectin in Daily Practice: Where Do We Stand in 2017? Digestion, 95 (4), 293–301. doi: http://doi.org/10.1159/000476062
Kanda, Y. (2012). Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplantation, 48 (3), 452–458. doi: http://doi.org/10.1038/bmt.2012.244
Rendek, Z., Falk, M., Grodzinsky, E., Wahlin, K., Kechagias, S., Svernlöv, R., Hjortswang, H. (2015). Effect of oral diclofenac intake on faecal calprotectin. Scandinavian Journal of Gastroenterology, 51 (1), 28–32. doi: http://doi.org/10.3109/00365521.2015.1066421
Wallace, J. L. (2011). NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. British Journal of Pharmacology, 165 (1), 67–74. doi: http://doi.org/10.1111/j.1476-5381.2011.01509.x
Lim, Y. J., Chun, H. J. (2013). Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges. Gastroenterology Research and Practice, 2013, 1–7. doi: http://doi.org/10.1155/2013/761060
Watanabe, T., Fujiwara, Y., Chan, F. K. L. (2019). Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review. Journal of Gastroenterology. doi: http://doi.org/10.1007/s00535-019-01657-8
Gubska, O. Y., Kuzminetes, А. А., Hutsul, V. M., Lavrenchuk, I. O. (2019). Intestinal microbiome and osteoarthritis. GASTROENTEROLOGY, 53 (2), 132–137. doi: http://doi.org/10.22141/2308-2097.53.2.2019.168988
Copyright (c) 2020 Olena Gubska, Andrii Kuzminets, Artem Panin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.